
    
      VE303 is a rationally-defined bacterial consortium candidate being developed for the
      prevention of recurrent C. difficile infection. VE303 consists of 8 types of clonal human
      commensal bacteria strains selected for their ability to provide colonization resistance to
      C. difficile and manufactured under GMP conditions.
    
  